Consolidated Edison, Inc. vs HCA Health Inc — how do they compare? Consolidated Edison, Inc. trades at $106.11 (market cap $38.70B), while HCA Health Inc trades at $443.69 (market cap $95.08B). The key difference: HCA Health Inc is far larger — about 2.5× Consolidated Edison, Inc.'s market cap, and Consolidated Edison, Inc. pays the higher dividend (3.36%). Which is the better fit depends on your goals — on Pluang, investors hold Consolidated Edison, Inc. for 75 Days and HCA Health Inc for 76 Days on average.
| ED | HCA | |
|---|---|---|
Market Cap | $38.70B | $95.08B |
Volume | 2,154,810 | 998,787 |
Sector | Utilities | Health |
52-Week High | $115.46 | $545.13 |
52-Week Low | $95.37 | $361.32 |
Typical Hold Time | 75 Days | 76 Days |
Enterprise Value | $65.55B | $145.62B |
Dividend Yield | 3.36% | 0.71% |
Signals from Pluang's Aura AI — not financial advice
ED (Consolidated Edison) trades at $105.99, up 0.83% today, near the consensus price target of $106.33. The stock shows a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, 2025 revenue grew to $16.92B with a net income margin of 12.53%, while recent earnings have been mixed with a Q1 2026 miss. The company maintains a solid dividend, with a recent $0.89 payout announced for September 2026, and is highlighted in news for its economic impact in New York and involvement in electric bus infrastructure.
Outlook is balanced; ED offers stability as a utility stock with consistent dividends and moderate growth, but faces risks from debt levels and interest expenses. Analyst sentiment is cautious with 62.96% hold ratings. Key catalysts include the upcoming investor presentation on October 6, 2026, and execution on capital investments. Risks involve regulatory changes and economic sensitivity.
HCA Healthcare (HCA) trades at $445.01, up 2.96% today, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $75.6B in 2025, with net income of $6.78B, and the stock trades at a P/E of 14.73. Analyst consensus is a Buy with a $461.12 price target, though ongoing legal investigations pose a headwind.
The outlook remains positive given solid demand and cost controls, but risks include payer-mix pressure and high debt levels. Upside potential exists if earnings growth continues, but investors should monitor legal developments and interest rate impacts on the leveraged balance sheet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities will generate nearly all of Con Ed's earnings once it closes the sale of its clean energy business to RWE. Con Ed's clean energy business owns the second-largest portfolio of utility-scale solar projects in the U.S. Following the sale, Con Ed's only non-utility earnings will come from investments in gas and electric transmission.
Read more on ED →HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →